RAFAEL LOCH BATISTA
Projetos de Pesquisa
Unidades Organizacionais
Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina - Médico
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/42 - Laboratório de Hormônios e Genética Molecular, Hospital das Clínicas, Faculdade de Medicina
Instituto do Câncer do Estado de São Paulo, Hospital das Clínicas, Faculdade de Medicina - Médico
LIM/42 - Laboratório de Hormônios e Genética Molecular, Hospital das Clínicas, Faculdade de Medicina
13 resultados
Resultados de Busca
Agora exibindo 1 - 10 de 13
conferenceObject Comparative Study of Silent Corticotrophic Adenomas and Null CELL Pituitary Adenomas(2014) BATISTA, Rafael Loch; NETO, Malebranche Cunha; BORBA, Clarissa Groberio; CESCATO, Valter Angelo Sperling; SILVA, Gilberto Ochman; MUSOLINO, Nina de Castro- Cabergoline in the Management of Residual Nonfunctioning Pituitary Adenoma A Single-Center, Open-Label, 2-Year Randomized Clinical Trial(2019) BATISTA, Rafael L.; MUSOLINO, Nina R. C.; CESCATO, Valter A. S.; SILVA, Gilberto O. da; MEDEIROS, Raphael S. S.; HERKENHOFF, Clarissa G. B.; TRARBACH, Ericka B.; CUNHA-NETO, Malebranche B.Background: Complete tumor removal by transsphenoidal surgery is usually difficult for large nonfunctioning pituitary adenomas (NFPAs). A validated medical treatment may be useful for their management. This study evaluates the clinical efficacy of the dopaminergic agonist cabergoline for residual NFPA. Design, Setting, and Participants: We conducted a randomized, parallel, open-label clinical trial that compared cabergoline with nonintervention in patients with residual NFPA after transsphenoidal surgery over 2 years. The primary outcome was clinical efficacy (tumor reduction). The secondary outcome was the relationship between tumor dopamine D2 receptor (D2R) expression and clinical responsiveness. Tumor measurements and clinical evaluations were performed every 6 months. Results: In total, 59 and 57 individuals were randomly assigned to the study and control groups, respectively. At the end of the study, residual tumor shrinkage, stabilization, and enlargement were observed in 28.8%, 66.1%, and 5.1% of patients, respectively, in the medical-therapy group and in 10.5%, 73.7%, and 15.8% of patients, respectively, in the control group (P=0.01). The progression-free survival rate was 23.2 and 20.8 months for the study and control groups, respectively (P=0.01). D2R was not associated with cabergoline responsiveness. No major side effects were related to cabergoline use. Conclusions: Cabergoline was an effective drug for treating residual NFPA, and its use was associated with a high rate of tumor shrinkage ( NCT03271918).
- Clinically nonfunctioning pituitary adenoma growth after radiosurgery(2012) BATISTA, Rafael Loch; TOSCANINI, Andrea Cecilia; GLEZER, Andrea; SIQUEIRA, Mario Gilberto; BENABOU, Salomon; FONOFF, Erick Talamoni; TAVARES, Wagner Malago; TEIXEIRA, Manoel Jacobsen; CUNHA NETO, Malebranche Berardo Carneiro da
conferenceObject Evolution of Cushing's Disease By Pituitary Carcinoma: A Diagnostic Challenge(2014) BATISTA, Rafael Loch; ALCANTARA, Ana Elsa Evangelista; BORBA, Clarissa Groberio; MUSOLINO, Nina de Castro; CESCATO, Valter Angelo Sperling; MACHADO, Vanielle Carvalho; CUNHA NETO, Malebranche Beraldo Carneiro daconferenceObject Immunohistochemistry Is NOT Predictive of Response to Cabergoline in Clinically Nonfunctioning Pituitary Adenomas(2014) BATISTA, Rafael Loch; MUSOLINO, Nina de Castro; BORBA, Clarissa Groberio; CESCATO, Valter Angelo Sperling; CUNHA NETO, MalebrancheconferenceObject IgG4-Related Hypophysitis(2014) BATISTA, Rafael Loch; BORBA, Clarissa Groberio; MACHADO, Vanielle Carvalho; ALCANTARA, Ana Elisa Evangelista; RAMOS, Luciano Silva; CUNHA NETO, MalebrancheconferenceObject Cabergoline Effectivenes in Patients with Clinically Nonfunctioning Pituitary Adenomas(2014) BATISTA, Rafael Loch; MUSOLINO, Nina de Castro; BORBA, Clarissa Groberio; CESCATO, Valter Angelo Sperling; SILVA, Gilberto Ochman; CUNHA NETO, Malebranche- Thickened Pituitary Stalk Associated with a Mass in the Sphenoidal Sinus: An Alarm to Suspect Hypophysitis by Immunoglobulin G4?(2015) BATISTA, Rafael Loch; RAMOS, Luciano Silva; CESCATO, Valter Angelo; MUSOLINO, Nina Rosa Castro; BORBA, Clarissa Groberio; SILVA, Gilberto Ochman; MORENO, Lilian Hupfeld; CUNHA NETO, Malebranche Bernardo CarneiroIntroduction: Hypophysitis is a chronic inflammation of the pituitary gland of complex and still incompletely defined pathogenesis. It belongs to the group of non-hormonesecreting sellar masses, sharing with them comparable clinical presentation and radiographic appearance. Objectives Describe the case of immunoglobulin G4 (IgG4)-related hypophysitis presenting as a mass in the sphenoid sinus. Resumed Report A 40-year-old Brazilian man had a diagnosis of central diabetes insipidus since 2001 associated with pituitary insufficiency. Pituitary magnetic resonance imaging revealed a centered pituitary stalk with focal nodular thickening and the presence of heterogeneous materials inside the sphenoid sinus. The patient was treated with testosterone replacement therapy. Laboratory results revealed increased IgG4 serum. Conclusion IgG4-related hypophysitis should be considered in patients with pituitary insufficiency associated with sellar mass and/or thickened pituitary stalk. IgG4 serum measurement for early diagnosis of IgG4-related hypophysitis should be performed.
bookPart Hipopituitarismo após Traumatismo Cranioencefálico(2015) BATISTA, Rafael Loch; CUNHA-NETO, Malebranche Berardo Carneiro daconferenceObject Recurrence of Craniopharyngioma Twice in Pacient Under Growth Hormone (GH) Replacement(2014) BORBA, Clarissa Groberio; BATISTA, Rafael Loch; ALCANTARA, Ana Elisa Evangelista; MACHADO, Vanielle Carvalho; NETO, Malebranche Cunha; MUSOLINO, Nina de Castro